Clinical application of the AMOY 9-in-1 panel to lung cancer patients

Abstract

AMOY had a higher success rate, shorter turnaround time, and higher detection rate than NGS panels. Only a limited number of mutant variants were included; thus be careful not to miss promising targetable driver mutations.